About us

Sumaya Biotech

Sumaya Biotech was founded in 2015 as a spin-out from the University of Heidelberg. We focus exclusively on the development of novel anti-Malaria vaccines and therapies. Our lead product, Sumavac-1, is an innovative Malaria vaccine based on the full-length MSP-1 protein which targets both liver and blood stages. Sumayavac-1 has successfully completed the first-in-man clinical trial in 2018 and is planned to start a Phase 1b trial in Africa in Q2 2022, including a controlled human malaria infection (CHMI) challenge.

Our follow up project is a small molecule, SC83288, with the goal to treat severe malaria in small children, pregnant women and infected travellers. SC83288 is planned to start a Phase I clinical trial in early 2023.

Sumaya Biotech has established a network of collaborations with external partners to advance our programs at low cost without compromising experimental strategies, know-how and excellence.
We have recently received considerable funding be the EU Malaria Fund. (See press release)

Prof. Dr. Dr. h.c Hermann Bujard

Hermann Bujard, a passionate scientist, an inspiring mentor and a generous friend

Sumaya Biotech mourns the loss of its founder Prof. Dr. Dr. h.c. Hermann Bujard who passed away on July 31, 2020.

We will miss him dearly.

Dr. Ernst Boehnlein (Managing Director)

Dr. Boehnlein studied biology at the Ruprecht-Karls-University of Heidelberg and graduated in 1986. He received his post-doctoral training at Duke University and at the Howard Hughes Medical Center at Duke Medical Center in Durham, NC. In 1989, he joined the Sandoz Research Institute in Vienna, Austria as group leader. In 1993 he became Director at Sandoz Pharmaceuticals and transferred a gene therapy project to Palo Alto where he co-directed a Sandoz-sponsored joint research program (Progenesys) with SyStemix, Inc. In 1995 he became a Director at SyStemix, Inc. In 1997, he joined the Novartis Institute for Biomedical Research as Executive Director in the Department of Arthritis and Bone Metabolism. In 2001, he moved back to Europe where he held senior management positions in start-up biotech companies in Düsseldorf, Göttingen and Munich. Since 2008, he is Managing Director at TET Systems in Heidelberg.